Understanding why some blood cancers stop responding to treatment

This research study is investigating how azacitidine — a medication used to treat high-risk myelodysplastic syndromes and certain acute leukemias — works in the body and why some patients stop responding to it. By studying blood samples from patients who have received this treatment, researchers hope to understand the underlying reasons for treatment resistance and potentially develop better combination therapies in the future.

While azacitidine has helped many patients with these blood cancers, doctors don't fully understand exactly how it works or why it eventually stops working for some people. This study aims to fill that knowledge gap so that future treatments can be more effective.